Table of Contents
Acute Myeloblastic Leukemia
Epidemiology
Etiology
Manifestations
Diagnosis
Classification
Genomics
Risk Stratification
Evaluation
Treatment
Supportive care
Acute Promyeoblastic Leukemia
Acute Myeloblastic Leukemia
Epidemiology
Most common acute leukemia in adults
Median age at diagnosis 65
M > F
Etiology
Can arise from an underlying hematologic disorder (MDS, ET/PV)
Consequency of prior therapy
Topoisomerase agents
Radiation
Chemical: smoking, dry cleaning, paint
Family/hereditary: Trisomy 21, Fanconi, ataxia telangectasia
Manifestations
Marrow failure: fatigue, dyspnea, easy bleeding/bruising, infection
Extramedullary spread
Lekemia cutis
Gingival involvement (M5 or ?myeloblastic)
Myeloid sarcoma
WBC variable
DIC in APL
Diagnosis
Blasts 20% in bone marrow or peripheral blood
Cytogenic t(8, 21), inv 10, t(15,17) often with less than 20%
Also sometimes less than 20% with myeloid sarcoma
Auer rods not always present, but nearly pathognomonic
Classification
FAB: M1 through M5
AML with MDS
AML NOS
Genomics
FLIP3
TP53
IDH1/IDH2
Risk Stratification
Risk category
Management
Poor
Treatment → transplant
complex karyotype, TP53
Intermediate
Treatment → transplant
Favorable
Treatment, no transplant
t(15,17) or APL
* Usually allogeneic transplant
Evaluation
H&P
ECOG
CBC with diff, CMP, uric acid, LDH
Coags
BM with cytogenetics and molecular studies
+/- CNS imaging if neuro symptoms
+/- LP (FLIP3, TP53, M5, etc.)
TTE/MUGA (anthrocyclines)
MUGA
Antimicrobials
Treatment
Induction: age, ECOG, cytogenics
Usually 7+3
Hypomethylating agent + venetoclax
older
unable to tolerate
complex cytogentics (TP53)
recheck BM in 28 days
Remission: less than 5% blasts
Consider reinduction if more than 5% blasts
5+3
higher intensity (cytarabine, FLAG-IDA, CLAG-M)
Consolidation
HIDAC 3-4 cycles
Liposomal cytarabine/daunorubicin 1-2 cycles
Hypomethylating agent + venetoclax
Other FDA approved drugs
Glasdegib
Ivosidenib
Enasidenib
?
Supportive care
Transfusions
Leukodepleted
irradiated
PPx
Prompt treatment of neutropenic fever
G-CSF/GM-CSF for septic shock: usually not given due to theoretical risk of inducing more blasts
Acute Promyeoblastic Leukemia
Highly curable
Frequently associated with DIC with previous regimen of cytarabine and daunorubicine
Tretinoin/Antimicrobials
side effect: differentiation syndrdome, treat with steroids
Arsenic Trioxide: monitor QT
Idarubicin? Mylotarg? For high-risk (WBC > 10)